TNIK Inhibition Has Dual Synergistic Effects on Tumor and Associated Immune Cells.
TNIK
colorectal cancer
immunogenic cell death
immunotherapy
kinase inhibitors
Journal
Advanced biology
ISSN: 2701-0198
Titre abrégé: Adv Biol (Weinh)
Pays: Germany
ID NLM: 101775319
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
revised:
14
04
2022
received:
08
02
2022
pubmed:
9
6
2022
medline:
24
8
2022
entrez:
8
6
2022
Statut:
ppublish
Résumé
Treatment with checkpoint inhibitors can be extraordinarily effective in a fraction of patients, particularly those whose tumors are pre-infiltrated by T cells. In others, efficacy is considerably lower, which has led to interest in developing strategies for sensitization to immunotherapy. Using various colorectal cancer mouse models, it is shown that the use of Traf2 and Nck-interacting protein kinase inhibitors (TNIKi) unexpectedly increases tumor infiltration by PD-1
Identifiants
pubmed: 35675910
doi: 10.1002/adbi.202200030
pmc: PMC9398996
mid: NIHMS1815157
doi:
Substances chimiques
Programmed Cell Death 1 Receptor
0
Protein Kinase Inhibitors
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2200030Subventions
Organisme : NCI NIH HHS
ID : P01 CA069246
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA079443
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA257623
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA240239
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA206890
Pays : United States
Informations de copyright
© 2022 The Authors. Advanced Biology published by Wiley-VCH GmbH.
Références
Nat Rev Drug Discov. 2018 May;17(5):353-377
pubmed: 29545548
Nat Commun. 2016 Aug 26;7:12586
pubmed: 27562646
BMC Genomics. 2014 Mar 13;15:190
pubmed: 24621249
Lancet. 2019 Oct 19;394(10207):1467-1480
pubmed: 31631858
Nat Commun. 2018 Jan 2;9(1):32
pubmed: 29296022
EMBO J. 2009 Nov 4;28(21):3329-40
pubmed: 19816403
Opt Lett. 2008 Jan 15;33(2):156-8
pubmed: 18197224
Nat Biotechnol. 2011 Oct 30;29(11):1046-51
pubmed: 22037378
J Biol Chem. 1999 Oct 22;274(43):30729-37
pubmed: 10521462
PLoS Biol. 2012;10(8):e1001376
pubmed: 22904686
Angew Chem Int Ed Engl. 2020 Apr 20;59(17):6839-6846
pubmed: 32004403
Pharmacol Ther. 2015 Dec;156:1-9
pubmed: 26542362
Nature. 2015 Jul 9;523(7559):231-5
pubmed: 25970248
J Biochem. 2012 Jan;151(1):47-55
pubmed: 21880693
Hum Cell. 2011 Sep;24(3):121-6
pubmed: 21710359
Cell. 2021 Aug 19;184(17):4512-4530.e22
pubmed: 34343496
Cancer Res. 2010 Jun 15;70(12):5024-33
pubmed: 20530691
J Immunother Cancer. 2019 Nov 28;7(1):328
pubmed: 31779705
Nature. 2017 Dec 7;552(7683):116-120
pubmed: 29186113
Proc Natl Acad Sci U S A. 2021 Nov 9;118(45):
pubmed: 34725151
Nat Rev Immunol. 2017 Feb;17(2):97-111
pubmed: 27748397
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Sci Rep. 2016 Sep 21;6:33534
pubmed: 27650168
Cancer Sci. 2017 May;108(5):818-823
pubmed: 28208209
Clin Cancer Res. 2021 Sep 1;27(17):4781-4793
pubmed: 34233961
Signal Transduct Target Ther. 2020 Mar 20;5(1):22
pubmed: 32296018
Bioessays. 2015 Aug;37(8):909-20
pubmed: 26115037
Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43
pubmed: 16344461
Nat Biotechnol. 2022 Apr;40(4):555-565
pubmed: 34795433
N Engl J Med. 2017 Dec 21;377(25):2500-2501
pubmed: 29262275
Immunity. 2016 Feb 16;44(2):343-54
pubmed: 26872698
J Biol Chem. 2004 Nov 19;279(47):49488-96
pubmed: 15342639
Oncotarget. 2016 Mar 29;7(13):16023-37
pubmed: 26910283
Am Soc Clin Oncol Educ Book. 2019 Jan;39:196-205
pubmed: 31099659
Nat Methods. 2021 Jan;18(1):43-45
pubmed: 33398191
Mol Med. 2017 Apr;23:50-56
pubmed: 28386621
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Mol Oncol. 2020 Dec;14(12):3083-3099
pubmed: 33021050
Oncoimmunology. 2020 Aug 31;9(1):1809947
pubmed: 32939327
Immunity. 2018 Dec 18;49(6):1148-1161.e7
pubmed: 30552023
BMC Cancer. 2015 Oct 24;15:794
pubmed: 26499327
Nat Commun. 2020 Apr 2;11(1):1632
pubmed: 32242021